Trivalent ganglioside vaccine and immunologic adjuvant versus adjuvant alone in metastatic sarcoma patients rendered disease-free by surgery: A randomized phase 2 trial

Authors :: David Hansen
Bartosz Chmielowski
G. Thomas Budd
Mark Agulnik
Gary K. Schwartz
Suzanne George
Joe Hirman
Christopher W. Ryan
Anthony D. Elias
Rashmi Chugh
Robin L. Jones
Cathryn M. Bennett
Philip O. Livingston
Paul L. Weiden
Richard D. Carvajal
William L. Read
Brian A. Van Tine
Hussein Tawbi
Robert G. Maki
Mohammed M. Milhem
Source :: Journal of Clinical Oncology. 32:10520-10520
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: 10520 Background: Recurrence after resection of metastatic sarcoma is common. The gangliosides GM2, GD2 and GD3 are strongly expressed on many sarcomas. The generation of anti-ganglioside antibodie...

Subjects :: Cancer Research
medicine.medical_specialty
Ganglioside
business.industry
medicine.medical_treatment
Disease free
Resection
Surgery
Oncology
Immunologic adjuvant
medicine
lipids (amino acids, peptides, and proteins)
Metastatic sarcoma
business
Adjuvant

Full Text Access

Tools